Document is current
Any future updates will be listed below
-
Authors
Ketvel, Laila
Keltikangas-Järvinen, Liisa
Pahkala, Katja
Juonala, Markus
Ahola-Olli, Ari
Lehtimäki, Terho
Viikari, Jorma
Raitakari, Olli
Rovio, Suvi
Saarinen, Aino https://orcid.org/0000-0003-4495-8360
-
Funding
Funding for this research was provided by:
Academy of Finland (grants 322098, 286284, 134309 (Eye), 126925, 121584, 124282, 255381, 256474, 283115, 319060, 320297, 314389, 338395, 330809, and 104821, 129378 (Salve), 117797 (Gendi), and 141071 (Skidi))
the Social Insurance Institution of Finland (the Social Insurance Institution of Finland)
Competitive State Research Financing of the Expert Responsibility area of Kuopio, Tampere and Turku University Hospitals (X51001)
Juho Vainion Säätiö (Juho Vainion Säätiö)
Paavo Nurmen Säätiö (Paavo Nurmen Säätiö)
Finnish Foundation for Cardiovascular Research (Finnish Foundation for Cardiovascular Research)
Suomen Kulttuurirahasto (Suomen Kulttuurirahasto)
Sigrid Juséliuksen Säätiö (Sigrid Juséliuksen Säätiö)
Tampereen Tuberkuloosisäätiö (Tampereen Tuberkuloosisäätiö)
Emil Aaltosen Säätiö (Emil Aaltosen Säätiö)
Yrjö Jahnssonin Säätiö (Yrjö Jahnssonin Säätiö)
Signe ja Ane Gyllenbergin Säätiö (Signe ja Ane Gyllenbergin Säätiö)
Diabetestutkimussäätiö (Diabetestutkimussäätiö)
Horizon 2020 (grant 755320 for TAXINOMISIS and grant 848146 for To Aition)
European Research Council (grant 742927 for MULTIEPIGEN project)
Tampere University Hospital Supporting Foundation (Tampere University Hospital Supporting Foundation)
Suomen kliinisen kemian yhdistys (Suomen kliinisen kemian yhdistys)
the Cancer Foundation Finland (the Cancer Foundation Finland)
University of Helsinki including Helsinki University Central Hospital
- License Information
-
More Information
Article History
Received: 16 November 2022
Revised: 11 January 2023
Accepted: 12 January 2023
First Online: 4 February 2023
Declarations
:
: A.A.-O. is an employee and shareholder of Abomics, a company offering pharmacogenetic consultation services.
: The study design has been approved by the ethical committees of all Finnish Universities with a medical faculty. All the participants or their parents (participants aged < 18 years) provided informed consent before participation. The YFS has been carried out in accordance with the Declaration of Helsinki.
